Premium
Adjuvant chemotherapy and outcomes in patients with nodal and resection margin‐negative pancreatic ductal adenocarcinoma: A systematic review and meta‐analysis
Author(s) -
Flaum Nicola,
Hubner Richard A.,
Valle Juan W.,
Amir Eitan,
McNamara Mairéad G.
Publication year - 2019
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25440
Subject(s) - medicine , oncology , resection margin , meta analysis , pancreatic ductal adenocarcinoma , adjuvant , chemotherapy , adjuvant chemotherapy , odds ratio , adjuvant therapy , adenocarcinoma , resection , nodal , pancreatic cancer , surgery , cancer , breast cancer
Adjuvant chemotherapy (AC) following pancreatic carcinoma (PC) resection improves overall survival (OS). A systematic review identified 10 phase‐2/3 studies investigating AC in 3644 patients looking at the influence of nodal and resection status. AC significantly improved disease free survival, OS and 5‐year odds of death risk. There was greater survival benefit in patients PS 0 and with body/tail tumors. There was a nonsignificant effect in N − /N + patients on OS and no difference between R0/R1 patients.